Want to see HK:2186 full AI Analyst Report?
Luye Pharma Group (2186) AI Stock Analysis
Luye Pharma Group
(HKEX:2186)
The score is driven primarily by solid profitability and a de-risking balance sheet, offset by a steep 2025 revenue contraction and historically inconsistent free cash flow. Technically, indicators point to weak-to-neutral momentum, while valuation looks reasonable on a ~11.6 P/E.
Luye Pharma Group (2186) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 28.00M
- Price to Earnings (P/E)
- 7.7
- Beta (1Y)
- 1.05
- Revenue Growth
- 2.84%
- EPS Growth
- 71.92%
- Country
- Hong Kong
- Employees
- 5,270
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Luye Pharma Group Business Overview & Revenue Model
Company Description
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments:...
How the Company Makes Money
Luye Pharma Group makes money primarily by selling pharmaceutical products (mainly prescription drugs) that it develops, manufactures (directly or via qualified manufacturing arrangements), and commercializes. Revenue is generated when products are p...
Luye Pharma Group Financial Statement Overview
Summary
Profitable with strong margins (gross ~66%, EBIT ~20%, EBITDA ~33% in 2025) and improving leverage (debt-to-equity ~0.59). However, a sharp 2025 revenue decline (~-37% YoY) and volatile free cash flow history (including negative FCF in 2024) weigh on quality and durability of performance.
Income Statement
62PositiveBalance Sheet
68PositiveCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.13B | 6.31B | 6.06B | 6.14B | 5.98B | 5.20B |
| Gross Profit | 3.91B | 4.16B | 4.04B | 4.20B | 4.14B | 3.40B |
| EBITDA | 1.92B | 2.06B | 1.92B | 2.08B | 1.81B | 906.88M |
| Net Income | 696.36M | 618.75M | 471.89M | 532.61M | 604.81M | -134.39M |
Balance Sheet | ||||||
| Total Assets | 34.87B | 32.84B | 29.61B | 25.49B | 24.25B | 22.58B |
| Cash, Cash Equivalents and Short-Term Investments | 10.76B | 8.88B | 6.50B | 6.11B | 5.54B | 5.51B |
| Total Debt | 12.54B | 9.42B | 10.32B | 8.42B | 9.10B | 9.49B |
| Total Liabilities | 17.30B | 14.19B | 13.86B | 11.96B | 13.21B | 13.47B |
| Stockholders Equity | 15.58B | 16.08B | 14.15B | 12.53B | 10.18B | 8.49B |
Cash Flow | ||||||
| Free Cash Flow | 1.04B | 780.44M | -1.54B | 430.23M | 490.14M | -1.36B |
| Operating Cash Flow | 972.90M | 1.78B | 167.76M | 1.60B | 1.65B | 182.37M |
| Investing Cash Flow | -3.01B | -3.99B | -1.47B | -1.42B | -1.66B | -3.44B |
| Financing Cash Flow | 3.48B | 1.79B | 2.96B | 841.60M | 54.15M | 1.88B |
Luye Pharma Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2186, the sentiment is Negative. The current price of 1.58 is below the 20-day moving average (MA) of 1.69, below the 50-day MA of 1.82, and below the 200-day MA of 2.26, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 34.04 is Neutral, neither overbought nor oversold. The STOCH value of 20.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2186.
Luye Pharma Group Peers Comparison
Overall Rating
HK:168187Outperform
HK:109365Neutral- HK:218659Neutral
HK:215753Neutral
HK:261646.6Neutral
HK:968846Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1681 | 87Outperform | HKD 12.54B | 9.38 | 25.10% | 5.11% | 15.05% | 20.58% |
| HK:1093 | 65Neutral | HKD 90.26B | 10.27 | 20.68% | 4.20% | 25.21% | 103.93% |
| HK:2186 | 59Neutral | HKD 6.23B | 7.73 | 4.40% | ― | 2.84% | 71.92% |
| HK:2157 | 53Neutral | HKD 5.69B | 19.79 | 17.36% | ― | 46.90% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2616 | 47Neutral | HKD 7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
| HK:9688 | 46Neutral | HKD 21.69B | -12.70 | -27.40% | ― | 5.38% | 16.86% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2186 | Luye Pharma Group | 1.58 | -1.64 | -50.78% | |
| HK:1093 | CSPC Pharmaceutical Group | 7.87 | 0.50 | 6.75% | |
| HK:9688 | Zai Lab Ltd | 17.37 | -3.65 | -17.36% | |
| HK:1681 | Consun Pharmaceutical Group Ltd. | 15.25 | 1.00 | 7.00% | |
| HK:2157 | Lepu Biopharma Co. Ltd. Class H | 3.15 | -3.23 | -50.55% | |
| HK:2616 | CStone Pharmaceuticals | 4.94 | -1.28 | -20.58% |
Luye Pharma Group Corporate Events
Luye Pharma Delivers Higher H1 Profit Despite Revenue Decline
Luye Pharma Group reported interim results for the six months ended 30 June 2026 showing a mixed performance, with revenue falling 5.6% to RMB3,002.1 million and gross profit down 11.8% to RMB1,902.3 million, although the gross margin remained relati...
Luye Pharma Advances HPV mRNA Vaccine LY01620 to Phase II in China
Luye Pharma Group is advancing its presence in therapeutic vaccines with LY01620, a Class 1 therapeutic biological mRNA vaccine targeting HPV16 E6/E7 antigens for cervical precancerous lesions and HPV-related tumors. The candidate is designed to indu...
Luye Pharma Sets Board Meeting to Approve Interim Results and Consider Dividend
Luye Pharma Group has scheduled a board meeting for 29 August 2026 to review and approve the interim results for the six months ended 30 June 2026, along with their planned publication. The board will also consider the potential payment of an interim...
Luye Pharma Advances CNS Portfolio With Successful U.S. Bridging Trial for LY03015
Luye Pharma Group has successfully completed a U.S. bridging clinical trial for LY03015, its in-house VMAT2 inhibitor and Sigma-1R agonist, designed to treat tardive dyskinesia and Huntington’s disease-related chorea. The study found comparable...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026